A detailed history of Israel Englander (Millennium Management LLC) transactions in Abb Vie Inc. stock. As of the latest transaction made, Millennium Management LLC holds 437,900 shares of ABBV stock, worth $78.8 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
437,900
Previous 980,232 55.33%
Holding current value
$78.8 Million
Previous $168 Million 48.57%
% of portfolio
0.04%
Previous 0.08%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $18.8 Million - $22.9 Million
114,751 Added 11.71%
1,094,983 $216 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $132 Million - $155 Million
854,846 Added 681.77%
980,232 $168 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $105 Million - $120 Million
-657,764 Reduced 83.99%
125,386 $22.8 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $45.1 Million - $50.8 Million
-327,790 Reduced 29.51%
783,150 $121 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $22.7 Million - $28.3 Million
171,401 Added 18.24%
1,110,940 $150 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $117 Million - $134 Million
807,485 Added 611.48%
939,539 $150 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $69.9 Million - $83.8 Million
-505,224 Reduced 79.28%
132,054 $21.3 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $73.6 Million - $84.4 Million
548,224 Added 615.61%
637,278 $85.5 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $49.9 Million - $63.5 Million
-362,772 Reduced 80.29%
89,054 $13.6 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $55.7 Million - $69.1 Million
-422,005 Reduced 48.29%
451,826 $73.2 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $25 Million - $31.6 Million
232,675 Added 36.29%
873,831 $118 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $38.4 Million - $43.6 Million
-361,369 Reduced 36.05%
641,156 $69.2 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $102 Million - $114 Million
973,668 Added 3374.11%
1,002,525 $113 Million
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $9.35 Million - $10.3 Million
-91,395 Reduced 76.0%
28,857 $3.12 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $3.51 Million - $4.73 Million
-43,572 Reduced 26.6%
120,252 $12.9 Million
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $60.6 Million - $71.1 Million
-705,346 Reduced 81.15%
163,824 $14.3 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $7.55 Million - $10.1 Million
102,886 Added 13.43%
869,170 $85.3 Million
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $62,500 - $94,758
-969 Reduced 0.13%
766,284 $58.4 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $47.9 Million - $59.9 Million
663,952 Added 642.74%
767,253 $67.9 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $43.3 Million - $52.1 Million
-687,799 Reduced 86.94%
103,301 $7.82 Million
Q2 2019

Aug 15, 2019

BUY
$65.7 - $83.98 $47.6 Million - $60.9 Million
724,775 Added 1092.76%
791,100 $57.5 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $22.9 Million - $29.3 Million
-348,498 Reduced 84.01%
66,325 $830,000
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $94.2 Million - $111 Million
-1,220,553 Reduced 74.63%
414,823 $33.4 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $95.6 Million - $106 Million
-1,075,736 Reduced 39.68%
1,635,376 $155 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $167 Million - $198 Million
1,864,703 Added 220.31%
2,711,112 $251 Million
Q1 2018

May 15, 2018

BUY
$92.01 - $123.21 $52.6 Million - $70.5 Million
572,179 Added 208.65%
846,409 $80.1 Million
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $20 Million - $21.9 Million
-222,855 Reduced 44.83%
274,230 $26.5 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $34.7 Million - $44.3 Million
497,085
497,085 $44.2 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.